{"id":"drug-semaglutide-administered-sc","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Constipation"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"20-30","effect":"Decreased appetite"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Hypoglycemia (when combined with insulin/sulfonylureas)"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion and reducing glucagon release. It also acts on the central nervous system to reduce appetite and increase satiety, leading to decreased caloric intake and weight reduction. These combined effects improve glycemic control and cardiovascular outcomes in patients with type 2 diabetes and obesity.","oneSentence":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:02.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in obese or overweight patients"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06500429","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist","status":"COMPLETED","sponsor":"Neurogastrx, Inc.","startDate":"2024-06-24","conditions":"Overweight and Obesity, Healthy","enrollment":120},{"nctId":"NCT07139548","phase":"PHASE3","title":"A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-08-31","conditions":"T2DM","enrollment":600},{"nctId":"NCT06974825","phase":"PHASE2","title":"A Study of BGM0504 in Chinese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2023-08-30","conditions":"Type 2 Diabetes","enrollment":67},{"nctId":"NCT06716216","phase":"PHASE3","title":"A Study of BGM0504 in Participants with Type 2 Diabetes","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-11-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":537},{"nctId":"NCT04238962","phase":"PHASE1","title":"A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-02-03","conditions":"Overweight, Obesity","enrollment":111},{"nctId":"NCT04012255","phase":"PHASE1","title":"A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-15","conditions":"Overweight, Obesity","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Drug: Semaglutide Administered SC","genericName":"Drug: Semaglutide Administered SC","companyName":"BrightGene Bio-Medical Technology Co., Ltd.","companyId":"brightgene-bio-medical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients, Cardiovascular risk reduction in patients with type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}